Diplomat Pharmacy Inc (NYSE:DPLO) has received a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $26.67.
A number of research analysts recently weighed in on DPLO shares. ValuEngine raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Zacks Investment Research lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $19.07, for a total transaction of $3,992,628.69. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.
DPLO stock opened at $19.84 on Thursday. Diplomat Pharmacy has a twelve month low of $14.50 and a twelve month high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63. The company has a market cap of $1.47 billion, a P/E ratio of 23.62 and a beta of 1.12.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, August 6th. The company reported $0.17 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.23 by ($0.06). Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.42 billion. During the same period last year, the business earned $0.25 EPS. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. Equities research analysts forecast that Diplomat Pharmacy will post 0.83 earnings per share for the current fiscal year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
See Also: Are analyst ratings accurate?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.